Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease

Mayo Clinic Proceedings

Volumn 74, Issue 4, 1999, Pages 371-375

  Ling, Lieng H ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; SPIRONOLACTONE;

AGED; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; CONSTRICTIVE PERICARDITIS; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG DISEASE; MALE; PARKINSON DISEASE; PATHOGENESIS;

EID: 0032905480     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.4.371     Document Type: Article

References (34)

1. Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-1984
2. Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neural 1994;51:1236-1241
3. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-212
4. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease [letter]. Lancet 1981;1:44
5. Tornling G, Unge G, Axelsson G, Noring L, Granerus AK. Pleuropulmonary reactions in patients on bromocriptine treatment. Eur J Respir Dis 1986;68:35-38
6. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;148:2231-2236
7. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991:30:613-616
8. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992;5:263-265
9. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-616
10. Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni
11. F, et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-728
12. Geminlan! G, Fetoni V, Genitrini S, Giovannini P, Tamma F, Caraceni T. Cabergoline in Parkinson's disease complicated by motor fluctuations. MovDisord 1996;11:495-500
13. Orlando RC, Moyer P, Barnett TB. Methysergide therapy and constrictive pericarditis. Ann Intern Med 1978;88:213-214
14. Harbin AD, Gerson MC, O'Connell JB. Simulation of acute myopericarditis by constrictive pericardial disease with endomyocardial fibrosis due to methysergide therapy. J Am Coll Cardiol 1984; 4:196-199
15. Kaminsky ME, Rodan BA, Osborne DR, Chen JT, Sealy WC, Putman CE. Postpericardiotomy syndrome. AJR Am J Roentgenol 1982; 138:503-508
16. Bufalino VJ, Robinson JA, Henkin R, O'Connell J, Gunnar R. Gallium67 scanning: a new diagnostic approach to the post-pericardiotomy syndrome. Am Heart J 1983;106:1138-1143
17. Lorell BH. Pericardial diseases. In: Braunwald E, editor. Heart Disease: A Textbook of Cardiovascular Medicine. Vol 2. 5th ed. Philadelphia: Saunders; 1997. pp 1478-1534
18. Wiggins J, Skinner C. Bromocriptine induced pleuropulmonary fibrosis. Thorax 1986:41:328-330
19. Killian DM, Furiasse JG, Scanlon PJ, Loeb HS, Sullivan HJ. Constrictive pericarditis after cardiac surgery. Am Heart J 1989;118:563-568
20. Saura J, Aguilar M, Allô J. Derrame pleural y pericarditis constrictiva secundarios al tratamiento con bromocriptina. Neurologia 1991; 6:331-333
21. Physicians' Desk Reference. 52nd éd. Montvale (NJ): Medical Economics; 1998. pp 589-592; 1890-1893
22. Ling LH, Oh JK, Seward JB, Danielson GK, Tajik AJ. Clinical profile of constrictive pericarditis in the modern era: a survey of 135 cases [abstract]. J Am Coll Cardiol 1996;27(Suppl A):32A-33A
23. Melmed S, Braunstein GD. Bromocriptine and pleuropulmonary disease [editorial]. Arch Intern Med 1989;149:258-259
24. Lera G, Vaamonde J, Muruzabal J, Obeso JA. Cabergoline: a longacting dopamine agonist in Parkinson's disease [letter]. Ann Neurol 1990:28:593-594
25. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993:43:25872590
26. Ribeiro P, Sapsford R, Evans T, Parcharidis G, Oakley C. Constrictive pericarditis as a complication of coronary artery bypass surgery. Br Heart J 1984:51:205-210
27. Oh JK, Hatle LK, Mulvagh SL, Tajik AJ. Transient constrictive pericarditis: diagnosis by two-dimensional Doppler echocardiography. Mayo Clin Proc 1993;68:1158-1164
28. Corrodi H, Fuxe K, Hökfelt T, Lidbrink P, Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 1973:25:409412
29. Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex. Gen Pharmacol 1986;17:57-62
30. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966:274:359-368
31. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sei 1967;254:1-12
32. Di Salle E, Ornati G, Briatico G. FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats. J Endocrinol Invest 1982;5(Suppl 1):45
33. Yeo T, Thorner MO, Jones A, Lowry PJ, Besser GM. The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells. Clin Endocrinol (Oxf) 1979;10:123-130
34. Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79-81